Eye Checkup
London, GB · 1 known investors
EyeCheckup is an AI software that analyzes retinal fundus images and OCT scans to screen for and grade more than 20 eye disease pathologies (including diabetic retinopathy, glaucoma, and age-related macular degeneration) as well as cardiovascular and chronic kidney disease. It is designed for eye screening without requiring an expert doctor's opinion or dilating eye drops, and integrates with non-mydriatic fundus cameras.
Also known as EyeCheckup
Investors · 1
Company profile
researched Aug 2026EyeCheckup is an artificial-intelligence software product that analyzes retinal fundus images and optical coherence tomography (OCT) scans to detect, grade and label retinal abnormalities. The company states the system identifies pathologies associated with more than 20 diseases, including diabetic retinopathy (more-than-mild and vision-threatening grades, plus clinically significant diabetic macular edema suspects), glaucoma (moderate and severe suspect categories), dry and wet age-related macular degeneration including geographic atrophy, retinal vein occlusion, hypertensive retinopathy and pathological myopia. Beyond ophthalmic conditions, the company says the same fundus-image analysis is used to indicate chronic kidney disease (CKD) and cardiovascular disease (CVD).
The software is intended to run alongside a non-mydriatic fundus camera: it analyzes each captured image, marks detected anomalies, and returns results within about three seconds per image, and it also flags invalid captures (clipped, fluorescent, overexposed, too dark, or closed-eye images) within about five seconds so they can be retaken. Outputs include a fundus analysis report and an OCT screening report. The company positions the tool as enabling screening and referral to a specialist without an expert doctor's opinion and without dilating eye drops. For OCT, the company states 11 distinct anomalies are detected, with use cases spanning screening, diagnosis and training.
Latest developments
The company states the project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101073762, and that the product was developed with support from the TÜBİTAK-TEYDEB support programme (project No 7220438), with product responsibility attributed to Ural Telekomünikasyon San. Tic. A.Ş.
▸Full profile — market position, technology, go-to-market, geography
Market position
The company contrasts EyeCheckup with comparable systems by the breadth of its outputs — pathologies linked to more than 20 diseases, plus CVD and CKD indications, rather than a single disease — and by validation across multiple prospective clinical trials and multiple camera types, including handheld hardware. It also emphasizes operation without pupil-dilating eye drops or an expert reader, and positions itself as affordable.
Technology
EyeCheckup applies hybrid deep learning algorithms to two image views per eye — macula-centered and optic-nerve-head-centered — and assigns disease severity levels according to clinical grading standards. The company reports 96% accuracy across three different cameras, including a handheld device, and describes accurate labeling of anomalies on fundus images in addition to disease-level classification. A separate model set analyzes OCT scans for 11 anomaly types. The company states it is the only AI eye-screening software developed in Europe validated in multiple prospective clinical trials, and that its glaucoma model is the only AI compared against a full clinical glaucoma diagnosis (with the corresponding article described as pending). A study of its diabetic retinopathy capability is described as published in Nature's Eye journal and evaluated at Moorfields Eye Hospital on 126,000 diabetes patients.
Go-to-market
The product is integrated with non-mydriatic fundus cameras, and the company maintains a dedicated sales and technical support center in Istanbul alongside a US contact office in San Francisco.
Screening settings that capture retinal images with non-mydriatic or handheld fundus cameras and OCT devices, where patients with suspected eye, cardiovascular or kidney disease can be triaged and referred to specialists without an on-site expert reader.
Geography
Headquarters at 124 City Rd, London, United Kingdom; a US office at Galvanize, 44 Tehama St, San Francisco, California; an R&D center at Akdeniz University Teknokent in Konyaaltı, Antalya, Türkiye; and a sales and technical support center in Levent, Beşiktaş, İstanbul, Türkiye.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsThe company states the project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101073762.
The product was developed with support from the TÜBİTAK-TEYDEB support programme, project No 7220438, with responsibility for the product attributed to Ural Telekomünikasyon San. Tic. A.Ş.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- Eye Checkupeye-checkup.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Eye Checkup do?
- EyeCheckup is an AI system that analyzes retinal fundus images and OCT scans to screen for eye, cardiovascular and kidney disease.
- Who are Eye Checkup's investors?
- Eye Checkup's investors include Techmine Gsyo.
- Where is Eye Checkup headquartered?
- Eye Checkup is headquartered in London, GB.